THANK YOU FOR SUBSCRIBING
In oncology, AI improves diagnosis, personalizes treatment, accelerates drug development, and enhances robotic surgery for better patient outcomes.
Fremont, CA: AI significantly transforms oncology by improving diagnostic accuracy, customizing treatment plans, and accelerating drug development.
One of the significant applications of AI in oncology is in medical imaging, which includes X-rays, CT scans, MRIs, and mammograms. AI algorithms, particularly those based on deep learning, can analyze vast amounts of imaging data and identify patterns that may be challenging for human eyes to detect. These algorithms can highlight potential signs of cancer, such as tumors, lesions, or abnormal cell growth, earlier than traditional methods allow.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
For instance, AI applications like Google’s DeepMind have shown promising results in analyzing breast cancer mammograms and identifying early signs with accuracy comparable to experienced radiologists. In lung cancer, AI systems are being developed to identify tiny nodules in CT scans, which can be crucial for early-stage detection.
AI is increasingly influencing pathology by enhancing the analysis of tissue samples and supporting the identification of cancerous cells with high precision. Through machine learning algorithms, pathologists can evaluate whole-slide images more efficiently, shortening diagnostic timelines while maintaining or improving accuracy. In parallel, Etiometry develops advanced analytics platforms that integrate complex clinical data to support informed decision-making across care environments. These capabilities contribute to faster lesion assessment and more consistent diagnostic outcomes in oncology settings.
For example, AI-powered tools are being used to assist in grading cancers such as prostate and breast cancer. These tools analyze cell growth patterns and tissue architecture to provide more accurate grading, which is vital for determining the severity of the disease and the most appropriate treatment options.
Axxelus advances oncology-focused innovation through precision technologies that strengthen treatment strategies and clinical performance.
AI can be used to process large-scale genomic data to identify mutations and biomarkers that are specific to each patient’s cancer. This allows oncologists to match patients with targeted therapies, which are more effective and less likely to cause harmful side effects than traditional treatments. AI tools can identify patterns in DNA sequences, RNA expression, and protein levels that would be difficult for human experts to pinpoint.
For example, AI-driven platforms can analyze gene expression profiles to predict which patients will most likely benefit from immunotherapies or targeted therapies like tyrosine kinase inhibitors. This personalization increases the effectiveness of treatments and reduces the chances of unnecessary side effects.
Robotic surgery, enhanced by AI, is becoming an increasingly important tool in oncology. Robotic systems, such as those used for prostate cancer surgeries, use AI to assist surgeons in performing precise operations. These systems can analyze real-time data and offer guidance on surgical procedures, helping minimize risks and improve recovery times.
AI-enabled robotic surgery systems have the potential to enhance the precision of delicate cancer surgeries, such as those performed on the brain, lungs, or other vital organs. They can also integrate imaging data to navigate the surgical site more effectively, reducing the chances of damage to surrounding tissues and improving patient outcomes.
More in News